We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Israeli Startup Claims to Have Genetically Edited Cannabis to Resist Mildew

The company says it is the first commercial organization to successfully edit a cannabis plant’s genome.

Read More

Canopy Growth’s Worm Study Finds CBD Is Safe for Long-Term Use

The Canadian cannabis giant's study suggests that lifelong CBD use is not only safe, it might just lengthen the average lifespan and increase activity levels in old age.

Read More

Unpacking the USDA’s Hemp Testing Framework

Why does hemp have to be reported on a dry-weight basis? What are the essential hemp testing procedures? Analytical Cannabis discusses the details of the USDA's hemp testing framework.

Read More

CBD Derivative Could Help Treat Huntington’s Disease and Rare Skin Diseases, Study Suggests

The CBD derivative molecule is an even more potent antioxidant and anti-inflammatory than CBD alone, the researchers claim.

Read More

California Awards Nearly $30 Million in Funding for Cannabis Research

California’s Bureau of Cannabis Control has awarded $29,950,494 in public university research grant funding to support cannabis-focused research projects in the state.

Read More

Cannabis Resin and Flower Are Much More Potent Than Fifty Years Ago, Study Finds

THC levels in resins have risen by nearly 25 percent over the past 50 years, according to researchers.

Read More

The Importance of Mass Spectrometry in Cannabis Testing

With the cannabis industry’s increasing acceptance and regulation, mass spectrometry has also become a technique near-indispensable to the analytical scientists working within the cannabis testing sector.

Read More

Determining Decarboxylation in the Cannabis Lab

Analytical Cannabis traces the origins of THC and CBD back to cannabigerolic acid (CBGA) and the reactions that change it.

Read More

Inside the ACI’s CBD Safety Trial

The Association for the Cannabinoid Industry's (ACI) own Paul Duffy tells Analytical Cannabis why it's crucial CBD companies have their toxicology data ready for next March, and how the ACI's own safety trial can help that happen.

Read More

Advertisement